ChinaDrugStatus

Dupilumab

度普利尤单抗
Brand: Dupixent / 达必妥·Immunology / Dermatology·Last verified 2026-11-20

IL-4Rα antibody whose 2026 NRDL payment scope expands from atopic dermatitis alone to 5 indications, adding prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #104 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to 5 indications: (1) Moderate-to-severe atopic dermatitis; (2) Adult moderate-to-severe prurigo nodularis; (3) Maintenance asthma in patients ≥6 years (type 2 inflammation with eosinophils ≥300/μL or OCS-dependent); (4) Uncontrolled eosinophilic COPD in adults (≥300/μL) on triple/dual therapy; (5) Adult bullous pemphigoid.
限:1.对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药;2.治疗适合系统治疗的中度至重度结节性痒疹的成人患者;3.6岁及以上儿童和成人哮喘患者的维持治疗(伴有2型炎症嗜酸性粒细胞≥300个/μL或口服糖皮质激素依赖性);4.三联/二联治疗未控制的嗜酸性粒细胞升高(≥300个/μL)慢性阻塞性肺疾病(COPD)成人患者维持治疗;5.治疗大疱性类天疱疮的成人患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #93NHSA · PDF p.136

Restricted to moderate-to-severe atopic dermatitis refractory, contraindicated, or intolerant to conventional therapy, per approved label.

限对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药。

2026 NRDL · #104NHSA · PDF p.126

Restricted to 5 indications: (1) Moderate-to-severe atopic dermatitis; (2) Adult moderate-to-severe prurigo nodularis; (3) Maintenance asthma in patients ≥6 years (type 2 inflammation with eosinophils ≥300/μL or OCS-dependent); (4) Uncontrolled eosinophilic COPD in adults (≥300/μL) on triple/dual therapy; (5) Adult bullous pemphigoid.

限:1.对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药;2.治疗适合系统治疗的中度至重度结节性痒疹的成人患者;3.6岁及以上儿童和成人哮喘患者的维持治疗(伴有2型炎症嗜酸性粒细胞≥300个/μL或口服糖皮质激素依赖性);4.三联/二联治疗未控制的嗜酸性粒细胞升高(≥300个/μL)慢性阻塞性肺疾病(COPD)成人患者维持治疗;5.治疗大疱性类天疱疮的成人患者。

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid.

    Chinese original: 支付范围由2025版单一项(特应性皮炎)扩增至5项,新增结节性痒疹、6岁及以上哮喘、嗜酸性粒细胞升高COPD及大疱性类天疱疮。

    NHSA · PDF p.126Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

度普利尤单抗注射液dosage name(NHSA)
Dupixentbrand en(WHO)
达必妥brand zh(NMPA)

Primary Sources for This Record